Evolution of Treatment Options for Patients With CRPC and Bone Metastases: Bone-Targeted Agents That Go Beyond Palliation of Symptoms to Improve Overall SurvivalDecember 16th 2011
This review will examine agents with potential activity in the palliation and treatment of skeletal metastases of prostate cancer, and will weigh the clinical-outcomes evidence for and against their broad use.
Contemporary Management of Locally Invasive Bladder CancerDecember 16th 2011
Muscle-invasive bladder cancer is an aggressive and potentially lethal disease. Integration of multimodal therapies, improved surgical techniques, and utilization of targeted agents has tremendously improved outcomes.
Select Interviews From the 2011 San Antonio Breast Cancer Symposium (SABCS) and American Society of Hematology (ASH) Annual MeetingDecember 16th 2011
As part of its coverage of SABCS, the cancernetwork.com spoke with C. Kent Osborne, MD, who is the director of both the Lester and Sue Smith Breast Center and the Dan L. Duncan Cancer Center at Baylor College of Medicine in Houston.
Bladder Cancer Treatment: Optimize, Don't CompromiseDecember 16th 2011
Patient selection based on a much more comprehensive biologic assessment of both host and tumor is likely the key to further advances in the treatment of all bladder cancer patients. Until such time, there can be no compromise in the careful application of the rigorous therapy required to optimize outcomes.
25 Years Later: Endangered Species or Successful Evolution?December 16th 2011
While ONCOLOGY has continued to evolve along with the field of oncology-for example, it now addresses critical issues of science and socioeconomics-it has remained true to the founding principles. Perhaps largely for this reason, the journal continues to be widely read across the entire oncology community.
Managing CRPC: Improving Symptoms, Survival, or Both?December 16th 2011
In addition to endeavors to develop new therapeutics, we should anticipate and prioritize studies that will address questions regarding the efficacy of combination therapy, timing and sequencing strategies, and the development of predictive markers to individualize and optimize therapy.
Are We Trumping Bone Disease in Prostate Cancer?December 16th 2011
We are seeing a new era in drug development with the identification of novel intra- and extracellular targets to which therapies are being directed. Perhaps more exciting is learning how to optimize standard therapies in combination with biologic agents and radiopharmaceuticals in order to target multiple pathways in prostate cancer growth. Stay tuned!
Challenges in the Modern Treatment of Muscle-Invasive Bladder CancerDecember 16th 2011
Still missing in our treatment of bladder cancer are the tools to accurately predict response to a specific therapy, whether it be chemotherapy, radiation, or transurethral resection alone. Once we have these tools, we will be well on our way to applying a more intelligent, true personalized medicine approach to the treatment of this disease.
Have the Changes in Treatment of Rectal Cancer Made a Significant Difference to Our Patients?December 15th 2011
Treatment for patients with locally advanced, resectable rectal cancer has clearly evolved, with significant refinements in preoperative assessment, surgical technique, and use of preoperative chemoradiation.
The Year in Oncology: Breakthroughs and ControversiesDecember 15th 2011
The past year in oncology was highlighted by the continuation of breakthroughs in targeted therapies-with new treatments receiving US Food and Drug Administration (FDA) approval for non–small-cell lung cancer (NSCLC), lymphoma, and melanoma.
Individualized Local Treatment Strategies for In-Transit MelanomaDecember 15th 2011
For localized in-transit disease, less is more, with local destruction, excision, and intralesional therapy being the cornerstones of treatment. If local therapies fail or if distant disease arises, isolated limb perfusion and systemic therapy remain effective options.
Treatment of In-Transit Melanoma: An Opportunity to Discover Critical KnowledgeDecember 15th 2011
While patients with in-transit disease represent a wide spectrum of disease that requires individualized therapy, great opportunity exists to learn from our treatment interventions in these individuals.
Transanal Excision of Rectal Cancer: A Work in ProgressDecember 15th 2011
The exact role of combined-modality therapy and TAE of rectal cancer remains to be defined. Certainly the stakes are high, as studies have shown that the recurrence of locally excised rectal cancer is associated with worse long-term survival outcomes.
The “Episode-of-Care” Payment Model: One Practice’s ExperienceDecember 15th 2011
The episode-of-care project is the first program in which a payer has partnered with the oncology community to reduce costs while paying for the demanding and complex cognitive work of the medical oncologist. The episode-of-care payment system seems to be working smoothly and we have not experienced the same erosion of our income that we have seen with other payers.
Chronicling Strides in Understanding and Managing Rectal CancerDecember 15th 2011
Advances in the treatment of rectal cancer, such as TME and CMT, have lengthened survival time and enhanced the quality of life. However, radiation therapy may have a negative impact on quality of life, especially in males. Future research needs to focus not only on survival but also on postoperative quality of life.
SABCS: Dramatic CLEOPATRA Findings Support Addition of Pertuzumab to Regimen for HER2-Positive Metastatic Breast CancerDecember 8th 2011
Addition of pertuzumab to a standard chemotherapy combination of trastuzumab and docetaxel led to a 38% reduction in risk of disease worsening or death in patients with HER2-positive metastatic breast cancer, reported investigators from the randomized, double-blind, placebo-controlled phase III CLEOPATRA study.
Light-Induced, Specific Killing of Cancer CellsNovember 7th 2011
Researchers have developed a novel way to molecularly target and kill cancer cells, called photoimmunotherapy. The method uses a monoclonal antibody against the epidermal growth factor coupled to a near-infrared dye. The result is a target-specific photosensitizer that causes specific cell death of cells bound by the antibody when NIR light is applied.